Omeros Corporation Announces Upcoming Presentations at 2024 European Hematology Association (EHA) Hybrid Congress
Omeros Corporation (Nasdaq: OMER) today announced that interim analysis data from its ongoing Phase 2 study of OMS906 in patients with paroxysmal nocturnal hemoglobinuria submitted to the 2024 European Hematology Association (EHA) Hybrid Congress has been selected for podium presentation.
- Omeros Corporation (Nasdaq: OMER) today announced that interim analysis data from its ongoing Phase 2 study of OMS906 in patients with paroxysmal nocturnal hemoglobinuria submitted to the 2024 European Hematology Association (EHA) Hybrid Congress has been selected for podium presentation.
- The EHA Congress will be held June 13-16, 2024, in Madrid, Spain.
- Two additional poster presentations directed to OMS906 will also be featured at the congress.
- The abstracts for all three presentations are scheduled to be published on May 14, 2024 and will be available on the EHA website at ehaweb.org .